Oelke Matthias, Shinghal Rajesh, Sontag Angelina, Baygani Simin K, Donatucci Craig F
Department of Urology, Hannover Medical School, Hannover, Germany.
Department of Urology, Palo Alto Medical Foundation, Palo Alto, California.
J Urol. 2015 May;193(5):1581-9. doi: 10.1016/j.juro.2014.11.094. Epub 2014 Nov 28.
Tadalafil once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia consistently shows statistically significant I-PSS improvements. However, physicians and patients wish to know whether tadalafil provides rapid, clinically meaningful improvement in lower urinary tract symptoms. In this post hoc analysis we integrated results from 4 placebo controlled studies to determine the duration of tadalafil once daily required to achieve clinically meaningful improvement.
We performed post hoc analysis of data integrated from 4 double-blind studies of tadalafil 5 mg and placebo once daily in 742 and 735 men, respectively, 45 years old or older with total I-PSS 13 or greater. Two clinically meaningful improvement categories were assessed, including 1) 3-point or greater baseline to end point total I-PSS improvement and 2) 25% or greater baseline to end point total I-PSS improvement. I-PSS was assessed at weeks 4, 8 and 12 in all studies, week 1 in 2 and week 2 in 1. Results in men treated with tadalafil who showed clinically meaningful improvement (responders) were further examined to determine the earliest time to clinically meaningful improvement.
Of 742 tadalafil treated patients 513 (69.1%) and 444 (59.8%) demonstrated category 1 and 2 clinically meaningful improvement, respectively, at the study end point. Of 234 category 1 responders with week 1 assessments 140 (59.8%) achieved clinically meaningful improvement by week 1 and 407 of the total of 513 category 1 responders (79.3%) showed it by week 4. Of the 205 category 2 responders with week 1 assessments 103 (50.2%) achieved clinically meaningful improvement by week 1 while 322 of the 444 category 2 responders (72.5%) did so by week 4.
Tadalafil 5 mg once daily led to clinically meaningful improvement in approximately two-thirds of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. More than half of this group of tadalafil treated responders achieved clinically meaningful improvement after 1 week of therapy and more than 70% did so within 4 weeks.
对于良性前列腺增生继发的下尿路症状,他达拉非每日一次持续显示出国际前列腺症状评分(I-PSS)在统计学上有显著改善。然而,医生和患者希望了解他达拉非是否能迅速带来临床上有意义的下尿路症状改善。在这项事后分析中,我们整合了4项安慰剂对照研究的结果,以确定他达拉非每日一次达到临床上有意义的改善所需的持续时间。
我们对分别来自4项他达拉非5毫克和安慰剂每日一次的双盲研究的数据进行了事后分析,这些研究的受试者为742名和735名45岁及以上、I-PSS总分13分及以上的男性。评估了两种临床上有意义的改善类别,包括:1)从基线到终点I-PSS总分改善3分或更多;2)从基线到终点I-PSS总分改善25%或更多。在所有研究中,于第4、8和12周评估I-PSS,在2项研究中于第1周评估,在1项研究中于第2周评估。对接受他达拉非治疗且显示出临床上有意义改善的男性(反应者)的结果进行进一步检查,以确定达到临床上有意义改善的最早时间。
在742名接受他达拉非治疗的患者中,分别有513名(69.1%)和444名(59.8%)在研究终点时显示出1类和2类临床上有意义的改善。在234名有第1周评估结果的1类反应者中,140名(59.8%)在第1周时达到临床上有意义的改善,在513名1类反应者总数中,407名(79.3%)在第4周时显示出这种改善。在205名有第1周评估结果的2类反应者中,103名(50.2%)在第1周时达到临床上有意义的改善,在444名2类反应者中,322名(72.5%)在第4周时达到这种改善。
他达拉非5毫克每日一次使约三分之二的良性前列腺增生继发下尿路症状男性获得临床上有意义的改善。在接受他达拉非治疗的这组反应者中,超过一半在治疗1周后达到临床上有意义的改善,超过70%在4周内达到。